$65.50 Million in Sales Expected for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) This Quarter

Equities research analysts forecast that ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Rating) will report sales of $65.50 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for ANI Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $64.70 million and the highest estimate coming in at $66.30 million. ANI Pharmaceuticals posted sales of $54.52 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 20.1%. The business is expected to report its next earnings report before the market opens on Monday, January 1st.

On average, analysts expect that ANI Pharmaceuticals will report full year sales of $294.00 million for the current year, with estimates ranging from $292.20 million to $295.80 million. For the next financial year, analysts expect that the company will report sales of $347.85 million, with estimates ranging from $347.80 million to $347.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow ANI Pharmaceuticals.

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) last issued its earnings results on Tuesday, March 15th. The specialty pharmaceutical company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.31). The firm had revenue of $60.93 million during the quarter, compared to the consensus estimate of $58.25 million. ANI Pharmaceuticals had a negative net margin of 19.71% and a positive return on equity of 14.10%. During the same period in the previous year, the company posted $0.65 earnings per share.

A number of analysts have weighed in on ANIP shares. Cantor Fitzgerald restated a “neutral” rating on shares of ANI Pharmaceuticals in a research report on Wednesday, March 16th. StockNews.com downgraded shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, April 27th. Raymond James reduced their price target on shares of ANI Pharmaceuticals from $65.00 to $47.00 and set an “outperform” rating for the company in a report on Wednesday, March 16th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, March 14th. Finally, TheStreet cut shares of ANI Pharmaceuticals from a “c-” rating to a “d+” rating in a report on Wednesday, March 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Hold” and an average target price of $56.67.

NASDAQ ANIP opened at $26.12 on Tuesday. The company has a current ratio of 3.68, a quick ratio of 2.74 and a debt-to-equity ratio of 0.86. The firm has a market capitalization of $451.14 million, a price-to-earnings ratio of -8.04 and a beta of 1.06. The firm’s 50 day simple moving average is $30.74 and its 200 day simple moving average is $38.70. ANI Pharmaceuticals has a 1 year low of $24.41 and a 1 year high of $60.23.

In related news, CEO Nikhil Lalwani acquired 7,224 shares of the business’s stock in a transaction dated Monday, March 21st. The shares were purchased at an average price of $27.69 per share, for a total transaction of $200,032.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Patrick D. Walsh bought 5,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, March 21st. The shares were acquired at an average cost of $27.76 per share, with a total value of $138,800.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 17,224 shares of company stock worth $477,083. 27.20% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Meeder Asset Management Inc. boosted its position in ANI Pharmaceuticals by 5,952.2% during the third quarter. Meeder Asset Management Inc. now owns 1,392 shares of the specialty pharmaceutical company’s stock worth $45,000 after purchasing an additional 1,369 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in ANI Pharmaceuticals by 23.9% during the 1st quarter. Mutual of America Capital Management LLC now owns 1,833 shares of the specialty pharmaceutical company’s stock worth $52,000 after buying an additional 354 shares during the last quarter. Metropolitan Life Insurance Co NY bought a new position in ANI Pharmaceuticals during the 3rd quarter worth approximately $95,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $196,000. Finally, Diker Management LLC acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at approximately $207,000. Institutional investors and hedge funds own 59.66% of the company’s stock.

About ANI Pharmaceuticals (Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.

Further Reading

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.